Articles related to Hematology/Oncology

“We are surprised and disappointed by this FDA decision for EBV+ PTLD patients who have a significant unmet need, highlighted by tabelecleucel’s orphan drug designation and by the granting of breakthrough status.” — Dr. Cokey Nguyen, Atara CEO

“Although historically grouped together, viral-associated PCNSL subtypes are biologically distinct diseases. Each escapes immune control through a different mechanism, creating fundamentally different tumor microenvironments.” – Melinda Burgess, Researcher from the Department of Haematology at Princess Alexandra Hospital

“A patient who is considered neutropenic, if they spike a low-grade temperature of 100.4, they can go from being alive and well to dead in three hours,” Palmeri testified, explaining why oncologists ultimately withdrew acute hematology services after documenting that nurses “were not checking temperature in the time frames that they’re supposed to check.”

Silent inactivation (where neutralizing antibodies reduce enzymatic activity without clinical symptoms) can go undetected without therapeutic drug monitoring, leading to subtherapeutic asparagine depletion and increased relapse risk.

PORT is recommended for patients with cSCC having close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome). In patients with cSCC, PORT is recommended for T3 and T4 tumors—both strong recommendations with moderate to low evidence quality.

What began as a seemingly routine migraine case quickly unraveled into a devastating example of how fear, misinformation, and delayed care can transform a curable condition into a terminal diagnosis.